GuidelineTransplantation and cellular therapy2022
Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Guideline in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Trial
- Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.Blood advances · 2024Trial
- Real-world treatment patterns of patients with large B-cell lymphoma over time and into a post-CAR T approval era.Blood advances · 2026Article
- Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.Transplantation and cellular therapy · 2026Article
- Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma.Transplantation and cellular therapy · 2025Article
- Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.Blood advances · 2025Article
- Sequencing Anti-CD19 Therapies in Diffuse Large B-Cell Lymphoma: From Mechanistic Insights to Clinical Strategies.International journal of molecular sciences · 2025Review
- CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.Journal for immunotherapy of cancer · 2025Review
- Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma.Bone marrow transplantation · 2025Article
- Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.Haematologica · 2025Article
- Isolator-based point-of-care manufacturing: a practical solution for GMP-compliant cell and extracellular vesicles therapy production.Frontiers in bioengineering and biotechnology · 2025Review
- Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.Transplantation and cellular therapy · 2025Article
- Article
- Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.Blood advances · 2024Article
- Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.Haematologica · 2024Article
- Fostering next generation transplant physicians.Blood cell therapy · 2024Article
- A STEP ahead for CAR-T cell therapy of large B cell lymphoma: understanding the molecular determinants of resistance.Translational cancer research · 2023Article
- Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.Blood advances · 2023Article
- Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.Transplantation and cellular therapy · 2023Article
- CAR-T Cell Therapy: the Efficacy and Toxicity Balance.Current hematologic malignancy reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
Abstract
Since 2017, 3 CD19-directed chimeric antigen receptor (CAR) T cell therapies-axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel-have been approved for relapsed/refractory aggressive diffuse large B cell lymphoma after 2 lines of therapy. Recently, 3 prospective phase 3 randomized clinical trials were conducted to define the optimal second-line treatment by comparing each of the CAR T cell products to the current standard of care: ZUMA-7 for axicabtagene ciloleucel, BELINDA for tisagenlecleucel, and TRANSFORM for lisocabtagene maraleucel. These 3 studies, although largely addressing the same question, had different outcomes, with ZUMA-7 and TRANSFORM demonstrating significant improvement with CD19 CAR T cells in second-line therapy compared with standard of care but BELINDA not showing any benefit. The US Food and Drug Administration has now approved axicabtagene ciloleucel and lisocabtagene maraleucel for LBCL that is refractory to first-line chemoimmunotherapy or relapse occurring within 12 months of first-line chemoimmunotherapy. Following the reporting of these practice changing studies, here a group of experts convened by the American Society for Transplantation and Cellular Therapy provides a comprehensive review of the 3 studies, emphasizing potential differences, and shares perspectives on what these results mean to clinical practice in this new era of treatment of B cell lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.